Efficacy of osimertinib in EGFR-mutant advanced NSCLC patients
WANG Linying
LUO Jianfeng
ZHU Dan
Abstract：Objective To investigate the efficacy of osimertinib as first-line therapy of patients with epidermal growth factor receptor(EGFR)mutation advanced non-small cell lung cancer(NSCLC)and its impact on immune function.Methods A total of 77 patients with EGFR mutation advanced NSCLC treated at Jinhua Municipal Central Hospital from October 2020 to September 2023 were retrospectively analyzed and divided into a control group(37 cases,treated with gefitinib)and an observation group(40 cases,treated with osimertinib)based on treatment regimens.The recent efficacy,tumor marker levels,T lymphocyte subset levels,quality of life,the incidence of adverse reactions and prognosis survival were compared between the two groups.Results The objective relief rate and disease control rate in the observation group(40.00%(16/40)and 85.00%(34/40))were higher than those in the control group(18.92%(7/37),62.16%(23/37)),and the differences were statistically significant(χ2=4.078,5.214,both P<0.05).After treatment,the levels of carcinoembryonic antigen,cytokeratin 19 fragment and neuron-specific eno-lase in the observation group((21.62±3.54)ng/mL,(8.94±1.72)ng/mL,(6.72±2.18)ng/mL)were lower than those in the control group((28.93±3.27)ng/mL,(13.62±2.35)ng/mL,(10.74±2.69)ng/mL),and the differences were statistically significant(t=9.390,10.025,7.229,all P<0.01).After treatment,the levels of CD3+,CD4+and CD4+/CD8+in the observation group((72.83±3.16)%,(48.59±3.12)%,(2.65±0.23))were higher than those in the control group((68.72±2.95)%,(43.82±2.94)%,(2.28±0.27)),and the differences were statistically significant(t=5.887,6.891,6.489,all P<0.01).The physical condition,family/social status,functional status,emotional status and additional attention status score in the observation group((23.14±5.81)points,(22.03±4.21)points,(23.24±3.69)points,(20.74±4.56)points and(32.74±5.43)points)were higher than those in the control group((19.73±4.69)points,(18.95±3.76)points,(18.72±4.15)points,(16.91±3.82)points and(28.09±6.75)points),and the differences were statistically sig-nificant(t=2.820,3.376,5.058,3.978,3.342,all P<0.01).No statistically significant differences were observed in the incidence of nausea and vomiting,fatigue,leukopenia,diarrhea and liver function impairment between the observation group and the control group(χ2=0.035,0.083,0.139,0.398,0.565,all P>0.05).The progression-free survival rate and overall survival rate of the observa-tion group(75.00%(30/40),85.00%(34/40))were higher than those of the control group(51.35%(19/37),62.16%(23/37)),and the differences were statistically significant(χ2=5.182,5.279,both P<0.05).Conclusion The first-line treatment with osimertinib has a good efficacy,safety and reliability for patients with EGFR mutation advanced NSCLC,and it can improve the prognosis.
Keywords：non-small cell lung cancerepidermal growth factor receptorosimertinibtherapeutic effectimmune function
Publication Date：2025-10-25
Online Publishing Date：2025-11-03(First online date of this platform, not the publication date of the document)
Pages：5( 1248-1252 )